Artelo Biosciences, Inc. (ARTL)
NASDAQ: ARTL · Real-Time Price · USD
0.7902
+0.0315 (4.15%)
At close: Aug 14, 2026, 4:00 PM EDT
0.8050
+0.0148 (1.87%)
After-hours: Aug 14, 2026, 7:53 PM EDT
Artelo Biosciences Employees
Artelo Biosciences had 7 employees as of December 31, 2025. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change
1
Growth
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,810,143
Market Cap
2.75M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7 | 1 | 16.67% |
| Jun 30, 2025 | 5 | 0 | - |
| Mar 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 6 | 0 | - |
| Sep 30, 2024 | 5 | 0 | - |
| Jun 30, 2024 | 5 | 0 | - |
| Mar 31, 2024 | 5 | 0 | - |
| Dec 31, 2023 | 6 | -1 | -14.29% |
| Sep 30, 2023 | 5 | 1 | 25.00% |
| Jun 30, 2023 | 5 | 1 | 25.00% |
| Mar 31, 2023 | 5 | 1 | 25.00% |
| Dec 31, 2022 | 7 | 3 | 75.00% |
| Sep 30, 2022 | 4 | - | - |
| Jun 30, 2022 | 4 | - | - |
| Mar 31, 2022 | 4 | - | - |
| Aug 31, 2020 | 3 | 2 | 200.00% |
| May 31, 2020 | 3 | 2 | 200.00% |
| Feb 29, 2020 | 3 | 2 | 200.00% |
| Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Feb 28, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| Virax Biolabs Group | 26 |
| Moleculin Biotech | 17 |
| Azitra | 13 |
| Jupiter Neurosciences | 5 |
| GRI Bio | 4 |
| Oragenics | 3 |
| 60 Degrees Pharmaceuticals | 3 |
ARTL News
- Just now - Artelo Biosciences Quarterly report: Q2 2026 - Filings
- 3 days ago - Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results - GlobeNewsWire
- 6 days ago - Artelo Biosciences doses first patient in DREAM study - TheFly
- 4 weeks ago - Artelo Biosciences Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Artelo Biosciences announces new ART26.12 data - TheFly
- 4 weeks ago - Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions - GlobeNewsWire
- 4 weeks ago - Artelo Biosciences Proxy statement: Proxy filing - Filings
- 4 weeks ago - Artelo Biosciences Proxy statement: Proxy filing - Filings